同期与序贯双心室辅助装置植入的时机与结局:胸外科医师学会Intermacs分析
基于胸外科医师学会Intermacs数据库,纳入2010年1月1日至2220年12月31日接受持久循环支持的成人患者,分为仅左心室辅助装置(LVAD)组、LVAD同期右心室辅助装置(RVAD)组和LVAD序贯RVAD组,采用倾向性评分匹配比较同期与序贯双心室辅助装置(BiVAD)的1年死亡率和不良事件。结果显示BiVAD组1年生存率低于仅LVAD组,匹配后同期BiVAD生存率优于序贯BiVAD。
要点
- BiVAD组1年生存率50.8%低于仅LVAD组的82.6%(log-rank P < .001)。
- 匹配后同期BiVAD的12个月生存率55.8%优于序贯BiVAD的41.8%(log-rank P < .001)。
- 序贯BiVAD组早期(<3个月)出血、感染、神经功能障碍和肾功能障碍不良事件率更高(P < .01)。
核心结论
- 匹配患者和疾病特征后,序贯BiVAD植入患者的结局比同期BiVAD植入患者更差。
研究设计与样本
- 回顾性分析胸外科医师学会Intermacs数据库,纳入2010年1月1日至2220年12月31日接受持久循环支持的年龄≥18岁成人。
- 数据集分为仅LVAD组(n = 27,325)、LVAD同期RVAD组(n = 1090)和LVAD序贯RVAD组(n = 556);采用倾向性评分匹配比较同期BiVAD(n = 565)与序贯BiVAD(n = 565)的1年死亡率和不良事件。
主要发现
- BiVAD队列1年总生存率显著差于仅LVAD队列(12个月生存率:50.8% vs 82.6%;log-rank P < .001)。
- 倾向性匹配队列中,同期BiVAD植入患者生存率优于序贯植入LVAD和RVAD者(12个月生存率:55.8% vs 41.8%;log-rank P < .001)。
- 序贯BiVAD组早期(<3个月)出血、感染、神经功能障碍和肾功能障碍不良事件率更高(P < .01)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Biventricular heart failure remains a clinically challenging condition to manage. Available literature describing the use of durable biventricular assist device (BiVAD) support has numerous limitations hindering the development of useful treatment algorithms. Analysis of BiVAD use within a large multicenter data set is needed to clarify outcomes associated with this therapy. METHODS: The Society of Thoracic Surgeons Intermacs database was queried to identify adults aged ≥18 years who received durable circulatory support from January 1, 2010, to December 31, 2220. The data set was divided into the following cohorts: (1) left ventricular assist device (LVAD) only (n = 27,325), (2) LVAD and concurrent right ventricular assist device (RVAD) (n = 1090), and (3) LVAD and sequential RVAD (n = 556). Propensity score matching was used to compare 1-year mortality and adverse events between concurrent (n = 565) and sequential BiVADs (n = 565). RESULTS: Overall survival within 1 year was significantly worse for the BiVAD cohort compared with the LVAD-only cohort (12-month survival: 50.8% vs 82.6%; log-rank P < .001). In a propensity-matched cohort, patients implanted with a BiVAD concurrently had an improved survival compared with those implanted an LVAD and an RVAD sequentially (12-month survival: 55.8% vs 41.8%; log-rank P < .001). Early (<3 months) adverse event rates were higher among patients receiving sequential BiVADs for bleeding, infection, neurologic dysfunction, and renal dysfunction (P < .01). CONCLUSIONS: After matching for patient and disease characteristics, patients with sequential BiVAD implantation have worse outcomes than patients with concurrent BiVAD implantation.
引用
- Ahmed MM, Jacobs JP, Meece LE, et al. Timing and Outcomes of Concurrent and Sequential Biventricular Assist Device Implantation: A Society of Thoracic Surgeons Intermacs Analysis. Ann Thorac Surg. 2023. PMID: 36935029. doi:10.1016/j.athoracsur.2023.02.058
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。